Barr Labs
Executive Summary
Generic manufacturer and FDA are scheduled to resume hearings in Newark federal court on Sept. 10. The trial had been suspended on Aug. 19 while attorneys for both sides attempted to negotiate a settlement. Originally, FDA asked the court to demand a halt in the manufacturing of 15 products, improvements in Barr's production and process testing for 45 other products and the recall of 30 lots of products.